Background: At my shop we have changed wholesale to the use of tenecteplase over alteplase for acute ischemic stroke meeting criteria for thrombolytic therapy. This was based on a systematic review and meta-analysis of 6 RCTs and 2 observational trials …
Background: Alteplase has been the accepted thrombolytic for acute ischemic stroke (AIS) for 25 years. However, recent data has emerged regarding tenectaplase as an alternative. Tenecteplase is a modified form of alteplase, with a lower cost and more favorable pharmacokinetic …
Background: The publication of the MR CLEAN trial in January 2015 changed the face of ischemic stroke care. This was the first study demonstrating a benefit to endovascular treatment of a specific subset of ischemic stroke patients: those with a …
Background: Alteplase is a tissue plasminogen activator that is approved for use prior to thrombectomy in ischemic strokes with the goal of reperfusion to ischemic areas of the brain. Tenecteplase is a recombinant enzyme derived from alteplase that is more …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
English
Chinese (Simplified)
French
German
Italian
Portuguese
Russian
Spanish
Turkish